By: IPP Bureau
Last updated : May 20, 2026 7:15 am
In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States
Apothecon Pharmaceuticals has announced the appointment of Shyamakant Giri as Group Chief Executive Officer of the Apothecon Group, marking a significant leadership addition as the company focuses on its next phase of growth and strategic expansion across India and global markets.
With more than 25 years of leadership experience across the pharmaceutical and healthcare sectors, Giri brings extensive expertise in managing businesses across regulated and emerging markets.
In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States.
Prior to joining Apothecon Group, Giri served as CEO of Gland Pharma Limited. Earlier, he was Managing Director and President – India & Rest of the World Markets at Amneal Pharmaceuticals, where he played a key role in driving business expansion and market growth. He has also held senior leadership positions at Abbott and other healthcare organisations over a career spanning nearly two decades.
The appointment is expected to strengthen Apothecon Group’s leadership capabilities as the company continues to expand its pharmaceutical business and global footprint.